Who
David Arkowitz
Director
Company insider
Files Form 4 as: Director, iBio; Director, Kineta, Inc./de; Chief Financial Officer, Seres Therapeutics; Director, F-star Therapeutics; Chief Financial Officer, Flexion Therapeutics; EVP, CFO and CBO, Amag Pharmaceuticals; Chief Financial Officer, Idenix Pharmaceuticals.
In numbers
- Trades disclosed
- 127
- Buys
- 13
- Sells
- 10
- Bought
- $470K
- Sold
- $382K
- Companies
- 7
- Companies where not an officer
- 3
- First trade
- 7 Mar 2006
- Last trade
- 14 Oct 2026
- Last filed
- 15 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Oct 2026filed 15 Oct 2026 | IBIO iBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 20 Nov 2025filed 24 Nov 2025 | IBIO iBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —13,500 at $0.00 | filing |
| 30 Jun 2025filed 2 Jul 2025 | Kineta, Inc./deoption or derivative | SEC FORM 4 Code D | —12,500 at $0.00 | filing |
| 30 Jun 2025filed 2 Jul 2025 | Kineta, Inc./deoption or derivative | SEC FORM 4 Code D | —20,000 at $0.00 | filing |
| 30 Jun 2025filed 2 Jul 2025 | Kineta, Inc./de | SEC FORM 4 Code D | —16,571 | filing |
| 25 Jun 2025filed 25 Jun 2025 | Kineta, Inc./de | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 23 Jun 2025filed 25 Jun 2025 | Kineta, Inc./deoption or derivative | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
| 23 Jun 2025filed 25 Jun 2025 | Kineta, Inc./de | SEC FORM 4 Code M | $7,62512,500 at $0.61 | filing |
| 23 Jun 2025filed 25 Jun 2025 | Kineta, Inc./de | SEC FORM 4 Code F | $1,2244,706 at $0.26 | filing |
| 10 Jan 2025filed 13 Jan 2025 | IBIO iBioBiotechnology | SEC FORM 4 Bought | $50K18,382 at $2.72 | filing |
| 21 Nov 2024filed 25 Nov 2024 | IBIO iBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —12,600 at $0.00 | filing |
| 4 Sep 2024filed 5 Sep 2024 | Kineta, Inc./deoption or derivative | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 16 Feb 2024filed 16 Feb 2024 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Sold | $4,2543,939 at $1.08 | filing |
| 15 Feb 2024filed 16 Feb 2024 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,625 at $0.00 | filing |
| 15 Feb 2024filed 16 Feb 2024 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Code M | —10,625 | filing |
| 14 Feb 2024filed 16 Feb 2024 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —213,750 at $0.00 | filing |
| 14 Feb 2024filed 16 Feb 2024 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —287,905 at $0.00 | filing |
| 14 Feb 2024filed 16 Feb 2024 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,625 at $0.00 | filing |
| 30 Oct 2023filed 31 Oct 2023 | MCRB Seres TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,4894,066 at $1.35 | filing |
| 27 Oct 2023filed 31 Oct 2023 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,209 at $0.00 | filing |
News
Head to Head Comparison: Myriad Genetics (NASDAQ:MYGN) & iBio (NASDAQ:IBIO)IBIO · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name David Arkowitz; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.